Cerus (CERS) Q2 FY26 earnings call

Cerus delivered solid Q2 FY26 results, driven by strong product revenue growth and momentum in its US Intercept Platelet and IFC franchises. The company raised its full-year product and IFC revenue guidance, reflecting confidence in continued double-digit growth and market penetration. Despite gross margin pressures from FX and inflation, Cerus maintained positive adjusted EBITDA and advanced its pipeline with key regulatory submissions and clinical trial progress, strengthening its financial foundation.